학술논문
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Document Type
ConferencePaper
Author
Brown, JR; Eichhorst, B; Hillmen, P; Lamanna, N; O'Brien, SM; Tam, CS; Qiu, LG; Kazmierczak, M; Jurczak, W; Zhou, KS; Simkovic, M; Mayer, J; Gillespie-Twardy, AL; Ferrajoli, A; Ganly, PS; Weinkove, R; Grosicki, S; Mital, A; Robak, T; Osterborg, A; Yimer, HA; Salmi, T; Wang, M; Fu, LN; Li, J; Wu, K; Cohen, A; Shadman, M
Source
BLOOD. 140:19-23
Subject
Language
English
English
English
ISSN
0006-4971